Style | Citing Format |
---|---|
MLA | Yaghmoori K, et al.. "Evaluation of the Associations Between Dry Mouth, Oral Lesions, and Orofacial Pain With Covid-19: A Systematic Review and Meta-Analysis." Journal of Pharmaceutical Negative Results, vol. 13, no. 4, 2022, pp. 1160-1166. |
APA | Yaghmoori K, Mousavi E, Khosravi S, Hatamzade Z, Ghahremani N, Amiri A (2022). Evaluation of the Associations Between Dry Mouth, Oral Lesions, and Orofacial Pain With Covid-19: A Systematic Review and Meta-Analysis. Journal of Pharmaceutical Negative Results, 13(4), 1160-1166. |
Chicago | Yaghmoori K, Mousavi E, Khosravi S, Hatamzade Z, Ghahremani N, Amiri A. "Evaluation of the Associations Between Dry Mouth, Oral Lesions, and Orofacial Pain With Covid-19: A Systematic Review and Meta-Analysis." Journal of Pharmaceutical Negative Results 13, no. 4 (2022): 1160-1166. |
Harvard | Yaghmoori K et al. (2022) 'Evaluation of the Associations Between Dry Mouth, Oral Lesions, and Orofacial Pain With Covid-19: A Systematic Review and Meta-Analysis', Journal of Pharmaceutical Negative Results, 13(4), pp. 1160-1166. |
Vancouver | Yaghmoori K, Mousavi E, Khosravi S, Hatamzade Z, Ghahremani N, Amiri A. Evaluation of the Associations Between Dry Mouth, Oral Lesions, and Orofacial Pain With Covid-19: A Systematic Review and Meta-Analysis. Journal of Pharmaceutical Negative Results. 2022;13(4):1160-1166. |
BibTex | @article{ author = {Yaghmoori K and Mousavi E and Khosravi S and Hatamzade Z and Ghahremani N and Amiri A}, title = {Evaluation of the Associations Between Dry Mouth, Oral Lesions, and Orofacial Pain With Covid-19: A Systematic Review and Meta-Analysis}, journal = {Journal of Pharmaceutical Negative Results}, volume = {13}, number = {4}, pages = {1160-1166}, year = {2022} } |
RIS | TY - JOUR AU - Yaghmoori K AU - Mousavi E AU - Khosravi S AU - Hatamzade Z AU - Ghahremani N AU - Amiri A TI - Evaluation of the Associations Between Dry Mouth, Oral Lesions, and Orofacial Pain With Covid-19: A Systematic Review and Meta-Analysis JO - Journal of Pharmaceutical Negative Results VL - 13 IS - 4 SP - 1160 EP - 1166 PY - 2022 ER - |